{"id":64537,"date":"2026-05-06T20:34:04","date_gmt":"2026-05-06T12:34:04","guid":{"rendered":"https:\/\/flcube.com\/?p=64537"},"modified":"2026-05-06T20:34:05","modified_gmt":"2026-05-06T12:34:05","slug":"ucb-to-acquire-candid-therapeutics-for-2-2b-gaining-best-in-class-bcma-t-cell-engager-cizutamig-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64537","title":{"rendered":"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases"},"content":{"rendered":"\n<p><strong>UCB (<a href=\"https:\/\/www.google.com\/finance\/quote\/UCB:EBR\">EBR: UCB<\/a>)<\/strong> announced on May 3, 2026, a definitive agreement to acquire <strong>Candid Therapeutics (&#8220;Candid&#8221;)<\/strong>, a privately held clinical-stage biotechnology company pioneering novel <strong>T-cell engagers (TCEs)<\/strong> for autoimmune and inflammatory diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount\/Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>$2 billion<\/strong><\/td><\/tr><tr><td><strong>Potential Milestone Payments<\/strong><\/td><td>Up to <strong>$200 million<\/strong><\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to <strong>$2.2 billion<\/strong><\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>End of Q2 \u2013 Early Q3 2026<\/td><\/tr><tr><td><strong>Conditions<\/strong><\/td><td>Subject to customary closing conditions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The acquisition represents UCB&#8217;s strategic expansion into next-generation immunotherapies for autoimmune conditions, complementing its existing portfolio in neurology and immunology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-amp-asset-profile\">Company &amp; Asset Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Company:<\/strong> Candid Therapeutics (private, clinical-stage)<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Autoimmune and inflammatory diseases<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Novel T-cell engagers (TCEs)<\/li>\n\n\n\n<li><strong>Lead Asset:<\/strong> <strong>Cizutamig<\/strong> \u2013 potential best-in-class BCMA TCE<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Bispecific antibody targeting BCMA on plasma cells and CD3 on T-cells<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cizutamig-clinical-development-status\">Cizutamig Clinical Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Development Stage<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Exposure<\/strong><\/td><td>Evaluated in <strong>over 100 patients<\/strong> across multiple myeloma and autoimmune diseases<\/td><\/tr><tr><td><strong>Current Studies<\/strong><\/td><td>Active clinical trials in <strong>over 10 autoimmune indications<\/strong><\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>Enables T-cell\u2013mediated cytotoxicity against BCMA-expressing plasma cells and B-cells<\/td><\/tr><tr><td><strong>Therapeutic Rationale<\/strong><\/td><td>Targets pathogenic plasma cells driving autoimmune disease pathology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Cizutamig represents a paradigm shift in autoimmune disease treatment by directly eliminating disease-causing plasma cells rather than broadly suppressing the immune system. The bispecific design engages T-cells to specifically target and destroy BCMA-expressing cells, offering potential for deeper and more durable responses.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-impact\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>UCB&#8217;s Immunology Leadership:<\/strong> Strengthens UCB&#8217;s position as a global leader in immunology with a differentiated cell-targeting approach<\/li>\n\n\n\n<li><strong>Autoimmune Disease Market:<\/strong> Addresses significant unmet need in conditions affecting over 50 million patients globally<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> First mover advantage in BCMA-targeted therapies for autoimmune indications<\/li>\n\n\n\n<li><strong>Pipeline Synergies:<\/strong> Complements UCB&#8217;s existing biologics and small molecule pipeline in immunology<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Leverages UCB&#8217;s established global commercial capabilities in immunology<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding transaction completion, clinical development timelines, and commercial expectations. Actual results may differ due to risks including regulatory approvals, closing conditions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2791,2015,131],"class_list":["post-64537","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-candid-therapeutics","tag-ebr-ucb","tag-ucb"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics (&quot;Candid&quot;), a privately held clinical-stage biotechnology company pioneering novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64537\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics (&quot;Candid&quot;), a privately held clinical-stage biotechnology company pioneering novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64537\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T12:34:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T12:34:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64537#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64537\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases\",\"datePublished\":\"2026-05-06T12:34:04+00:00\",\"dateModified\":\"2026-05-06T12:34:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64537\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Candid Therapeutics\",\"EBR: UCB\",\"UCB\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64537#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64537\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64537\",\"name\":\"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-06T12:34:04+00:00\",\"dateModified\":\"2026-05-06T12:34:05+00:00\",\"description\":\"UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics (\\\"Candid\\\"), a privately held clinical-stage biotechnology company pioneering novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64537#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64537\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64537#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics (\"Candid\"), a privately held clinical-stage biotechnology company pioneering novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64537","og_locale":"en_US","og_type":"article","og_title":"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases","og_description":"UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics (\"Candid\"), a privately held clinical-stage biotechnology company pioneering novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.","og_url":"https:\/\/flcube.com\/?p=64537","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-06T12:34:04+00:00","article_modified_time":"2026-05-06T12:34:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64537#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64537"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases","datePublished":"2026-05-06T12:34:04+00:00","dateModified":"2026-05-06T12:34:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64537"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Candid Therapeutics","EBR: UCB","UCB"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64537#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64537","url":"https:\/\/flcube.com\/?p=64537","name":"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-06T12:34:04+00:00","dateModified":"2026-05-06T12:34:05+00:00","description":"UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics (\"Candid\"), a privately held clinical-stage biotechnology company pioneering novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64537#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64537"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64537#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64537"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64537\/revisions"}],"predecessor-version":[{"id":64538,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64537\/revisions\/64538"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}